30亿元负债下的“奔跑”，卓正医疗三闯IPO

Core Viewpoint - Zhuozheng Medical is targeting the middle-class market and has submitted its IPO application to the Hong Kong Stock Exchange for the third time, showing significant revenue growth but facing increasing debt issues [1][3]. Financial Performance - Revenue increased from RMB 473.2 million in 2022 to RMB 958.6 million in 2024, with a projected revenue of RMB 695.7 million for the first eight months of 2025 [2][3]. - The company reported a net profit of RMB 80.2 million in 2024, marking its first positive operating profit since 2021, with a net profit of RMB 83.2 million for the first eight months of 2025 [3][4]. - Gross profit margin improved from 9.3% in 2022 to 23.6% in 2024, attributed to increased operational efficiency and economies of scale [5]. Debt and Financial Pressure - As of the end of 2024, total liabilities reached RMB 30.85 billion, with current liabilities rising from RMB 22.62 billion in 2022 to RMB 27.04 billion by August 2025 [1][7]. - The company faces significant liquidity pressure, with cash and cash equivalents of only RMB 1.58 billion against current liabilities of RMB 27.04 billion [7]. Business Expansion and Strategy - Zhuozheng Medical plans to use the net proceeds from the IPO for expanding its offline medical network, including relocating existing facilities and opening new ones in key cities like Hangzhou and Shanghai [8]. - The company aims to enhance its AI capabilities and collaborate with external research institutions to innovate medical services and improve operational efficiency [8]. Cost Management - Administrative expenses decreased significantly, with a reduction of 20.96% from RMB 1.77 billion in the first eight months of 2024 to RMB 1.4 billion in 2025, primarily due to the completion of employee stock incentive plans [5][6].